Endocrine
Endocrine dysregulation is the hallmark of modern chronic disease, with insulin resistance (IR) playing a central role. Research surrounding treatments to such disorders are complicated due to complex hormonal regulation of homoeostasis, with the liver playing a central role. Yet recognising the common pathology provides a more universally applicable approach to treatment: the target and regulation of insulin. Therapeutic carbohydrate restriction (TCR) has efficacy in regulating insulin, often without the need for, or with the deprescription of, pharmacotherapeutics. The most evidence for TCR focuses on its induced remission of metabolic syndrome (MetS), IR, and type 2 diabetes (T2D). Emerging research also supports its use for type 1 diabetes (T1D), polycystic ovarian syndrome (PCOS) and regulation of the thyroid and the hypothalamic-pituitary-adrenal-axis. Overall, TCR is promising in the treatment of endocrine disorders, often surpassing many medications prescribed to treat them.
